FrancophonIA/ELRC3.0 huggingface dataset:
English: Results also from a series of laboratory safety trials performed with vaccines of similar composition but including different bluetongue serotypes (including studies in pregnant ewes and cows) were presented in order to extrapolate safety conclusions.
Estonian: Ohutustulemuste ekstrapoleerimiseks esitati mitme laboratoorse katse tulemused (muuhulgas ka uuringud tiinetel uttedel ja lehmadel) ka vaktsiinide kohta, millel on sarnane koostis, kuid mis sisaldavad lammaste katarraalse palaviku viiruse muid serotüüpe.
English: BTVPUR AlSap 1 is a vaccinethat is available as a suspension for injection.
Estonian: BTVPUR AlSap 1 on vaktsiin, mida turustatakse süstesuspensioonina.
English: Why has BTVPUR AlSap 1 been approved?
Estonian: Miks BTVPUR AlSap 1 heaks kiideti?
English: What is BTVPUR AlSap 1 used for?
Estonian: Milleks BTVPUR AlSap 1 kasutatakse?
English: BTVPUR AlSap 1 was initially authorised under ‘exceptional circumstances'.
Estonian: Vaktsiinile BTVPUR AlSap 1 anti müügiluba algselt erandkorras.
English: Inactivated adjuvanted vaccine against bluetongue disease virus serotype 1
Estonian: Lammaste katarraalse palaviku viiruse serotüübi 1 vastane vaktsiin (inaktiveeritud, adjuveeritud)
English: Other information about BTVPUR AlSap 1:
Estonian: Muu teave vaktsiini BTVPUR AlSap 1 kohta
English: How has BTVPUR AlSap 1 been studied?
Estonian: Kuidas vaktsiini BTVPUR AlSap 1 uuriti?
English: What is the risk associated with BTVPUR AlSap 1?
Estonian: Mis riskid vaktsiiniga BTVPUR AlSap 1 kaasnevad?
English: What benefit has BTVPUR AlSap 1 shown during the studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini BTVPUR AlSap 1 kasulikkus?
English: How does BTVPUR AlSap 1 work?
Estonian: Kuidas BTVPUR AlSap 1 toimib?
English: The European Commission granted a marketing authorisation valid throughout the European Union, for ProteqFlu-Te on 6 March 2003.
Estonian: Euroopa Komisjon andis ProteqFlu-Te müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 6. märtsil 2003.
English: The effectiveness of ProteqFlu-Te was first assessed in several laboratory and field studies.
Estonian: ProteqFlu-Te efektiivsust hinnati esmalt mitmes labori- ja väliuuringus.
English: In case of increased risk of infection or insufficient intake of colostrum (first milk), an additional initial injection can be given at the age of 4 months, followed by the full vaccination programme (primary vaccination and following revaccinations).
Estonian: Suurenenud infektsiooniriski või ternespiima (esimese piima) ebapiisava tarbimise korral võib täiendava esmase süste teha 4 kuu vanuselt, millele järgneb täielik vaktsineerimisprogramm (esmane vaktsineerimine ja sellele järgnevad kordusvaktsineerimised).
English: The vaccine also stimulates protection against tetanus to prevent mortality.
Estonian: Vaktsiin stimuleerib ka kaitset teetanuse vastu, et ennetada suremust.
English: Horses are among the most susceptible species to tetanus.
Estonian: Hobused on üks teetanusele kõige tundlikumaid liike.
English: Other information about ProteqFlu-Te:
Estonian: Muu teave ProteqFlu-Te kohta
English: Tetanus is an acute, often fatal disease caused by the neurotoxin of the bacterium Clostridium tetani.
Estonian: Teetanus on äge sageli surmav haigus, mida põhjustab bakteri Clostridium tetani tekitatav neurotoksiin (närvimürk).
English: The muscle stiffness usually starts from the jaw and neck, then affects the whole body.
Estonian: Lihaste jäikus algab tavaliselt lõuast ja kaelast ning levib kõigisse lihastesse.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of ProteqFlu-Te exceed the risks for the approved indication and recommended that ProteqFlu-Te be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et heakskiidetud näidustustel on ProteqFlu-Te kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
English: The disease, which usually originates from contaminated wounds, is characterised by overall rigidity (stiffness) and convulsive spasms of the muscles.
Estonian: Tavaliselt lähtub haigus saastunud haavadest ning sellele on iseloomulik üldine rigiidsus (jäikus) ja lihaste kramplikud kokkutõmbed.
English: Horses should receive a primary vaccination, consisting of two injections at 5-6 months of age, given 4-6 weeks apart.
Estonian: Hobustele tuleb 5-6 kuu vanuses teha primaarne vaktsineerimine, mis koosneb kahest 4-6-nädalase vahega manustatavast süstest.
English: ProteqFlu-Te is a vaccine for use in horses.
Estonian: ProteqFlu-Te on hobustel kasutatav vaktsiin.
English: ProteqFlu-Te contains an adjuvant (carbomer) to enhance the immune response.
Estonian: ProteqFlu-Te sisaldab parema immuunvastuse saamiseks ka adjuvanti (karbomeeri).
English: The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for consumption or milk used for consumption.
Estonian: Keeluaeg on alates ravimi manustamisest arvestatav aeg, mille jooksul ei tohi looma tappa ega tema liha või piima toiduks tarvitada.
English: The withdrawal period for ProtequFlu-Te for meat and milk is zero days.
Estonian: Vaktsiini ProteqFlu-Te keeluaeg liha ja piima korral on 0 päeva.
English: Why has ProteqFlu-Te been approved?
Estonian: Miks ProteqFlu-Te heaks kiideti?
English: What is the risk associated with ProteqFlu-Te?
Estonian: Mis riskid ProteqFlu-Tega kaasnevad?
English: This means that a gene from two different equine influenza strains (A/eq/Ohio/03 and A/eq/Richmond/1/07) was inserted in to the canarypox vector viruses, which do not produce disease in horses, allowing the vector to produce specific proteins from these influenza strains.
Estonian: ProteqFlu-Te on vaktsiin, mida toodetakse rekombinant-DNA-tehnika abil: hobuste gripi viiruse kahe eri tüve geen (A/eq/Ohio/03 ja A/eq/Richmond/1/07) sisestatakse kumbki viirusvektorina kanaarilindude rõugete viirusesse, mis ei tekita haigust hobustel ja võimaldab vektoril toota nende gripiviiruste tüvede osi (spetsiifilisi valke).
English: The vaccine also contains a tetanus toxoid which is a tetanus toxin processed in order to decrease its toxic effect, but retain its antigenic power.
Estonian: Vaktsiin sisaldab ka teatud teetanusetoksoidi, mis on teetanusetoksiin (mürk), mida on töödeldud nii, et on vähenenud toksilisus, kuid säilinud antigeenne toime.
English: In laboratory studies, horses were challenged (infected) with equine influenza virus and the clinical signs and the excretion of the influenza virus after the challenge were compared between vaccinated and control animals (non-vaccinated animals or those vaccinated with a competitive product).
Estonian: Laboriuuringutes nakatati hobused hobuste gripi viirusega ning vaktsineeritud ja kontroll-loomadel (vaktsineerimata loomad või konkureeriva ravimiga vaktsineeritud loomad) võrreldi gripiviiruse nakatumisjärgseid kliinilisi tunnuseid ja viiruse eritumist.
English: ProteqFlu-Te is used to vaccinate horses from 4 months of age against equine influenza and tetanus.
Estonian: ProteqFlu-Ted kasutatakse vähemalt 4 kuu vanuste hobuste vaktsineerimiseks hobuste gripi ja teetanuse vastu.
English: The measure of effectiveness in all studies was antibody levels of against the two influenza vaccine strains and against tetanus toxoid.
Estonian: Efektiivsuse näitaja kõikides uuringutes oli gripivaktsiini mõlema tüve ja teetanusetoksoidi vastu tekkivate antikehade sisaldus.
English: This will help to protect against equine influenza and tetanus.
Estonian: See aitab kaitsta hobuste gripi ja teetanuse eest.
English: It contains parts of two equine influenza (flu) strains, which have been inserted into two canarypox vector (carrier) viruses respectively, and a tetanus toxoid (chemically weakened toxins from the tetanus bacterium).
Estonian: See sisaldab hobuste gripi viiruse kahe tüve komponente, mis on kumbki sisestatud viirusvektorina (kandjana) toimivasse kanaarilindude rõugete viirusesse, ja teatud teetanusetoksoidi (teetanusebakteri keemiliselt nõrgestatud toksiinid).
English: Equine influenza and tetanus vaccine
Estonian: ProteqFlu-Te hobuste gripi ja teetanuse vaktsiin
English: This should be followed by revaccination 5 months later, and afterwards by booster vaccinations every two years for protection against tetanus or for protection against influenza vaccination every year alternating with ProteqFlu or ProteqFlu-Te, respecting an interval of maximum two years for tetanus.
Estonian: Sellele peab 5 kuu pärast järgnema kordusvaktsineerimine ja seejärel iga kahe aasta tagant revaktsineerimine teetanuse vastu või igal aastal gripivastane vaktsineerimine vaheldumisi
English: When ProteqFlu-Te is given to horses, the animals' immune system recognises the specific proteins from the equine influenza strains and the tetanus toxoid as ‘foreign' and makes antibodies against them.
Estonian: Kui hobusele manustatakse ProteqFlu-Ted, peab immuunsüsteem hobuste gripi viiruse spetsiifilisi valke võõraks ning tekitab nende vastu antikehi.
English: The current formulation of ProteqFlu-Te produced similar antibody responses against the two flu strains and tetanus toxoid included in the vaccine to those seen in the main studies.
Estonian: ProteqFlu-Te praegune koostis tekitas vaktsiinis sisalduva kahe gripitüve ja teetanusetoksoidi vastu antikehi põhiuuringuga sarnasel tasemel.
English: The studies showed that ProteqFlu-Te was effective in reducing clinical signs and virus excretion after infection with equine influenza, and against tetanus to prevent mortality from 14 days after primary vaccination.
Estonian: Uuringud näitasid, et ProteqFlu-Te on hobuste gripi viiruse kliiniliste tunnuste ja nakatumisjärgse viiruse eritumise vähendamisel efektiivne, samuti mõjub vaktsiin teetanuse vastu, ennetades suremust 14 päeva pärast esmast vaktsineerimist Vaktsineerimise kaitse kestis 5 kuud pärast esmast vaktsineerimist, üks aasta hobuste gripi vastu ja kaks aastat teetanuse vastu pärast kolmandat vaktsineerimist.
English: How does ProteqFlu-Te work?
Estonian: Kuidas ProteqFlu-Te toimib?
English: How has ProteqFlu-Te been studied?
Estonian: Kuidas ProteqFlu-Ted uuriti?
English: What benefit has ProteqFlu-Te shown during the studies?
Estonian: Milles seisneb uuringute põhjal ProteqFlu-Te kasulikkus?
English: What is ProteqFlu-Te used for?
Estonian: Milleks ProteqFlu-Ted kasutatakse?
English: What is ProteqFlu-Te?
Estonian: Mis on ProteqFlu-Te?
English: The immune system will then be able to make those protective antibodies more quickly when the animal is naturally exposed to the equine flu viruses and the tetanus bacterium.
Estonian: Kui hobune puutub hobuste gripi viirusega ja teetanusebakteritega hiljem uuesti kokku, on immuunsüsteem võimeline tekitama antikehi kiiremini.
English: It may request a reexamination of the opinion within 15 days of receipt of notification of this negative opinion.
Estonian: Ettevõte võib taotleda arvamuse taasläbivaatamist 15 päeva jooksul pärast negatiivse arvamuse teate saamist.
English: The company presented the results of 4 main studies involving a total of 588 patients.
Estonian: Ettevõtte esitas kokku 588 patsienti hõlmanud 4 põhiuuringu tulemused.
English: The company that applied for authorisation is Renable Pharma Limited.
Estonian: Müügiluba taotles Renable Pharma Limited.
English: What is EnCyzix?
Estonian: Mis on EnCyzix?
English: This stops the release of other hormones called gonadotrophins, which are needed for the testes to produce testosterone and to work normally.
Estonian: See peatab gonadotropiinideks nimetatavate teiste hormoonide vabanemise, mida munandid vajavad testosterooni tootmiseks ja normaalseks toimimiseks.
English: Overweight men with hypogonadotropic hypogonadism produce too much of the hormone oestrogen.
Estonian: Hüpogonadotroopse hüpogonadismiga ülekaalulised mehed toodavad liiga palju hormooni östrogeen.
English: The main measures of effectiveness were the amount of sperm produced and testosterone levels.
Estonian: Efektiivsuse põhinäitajad olid tekkinud spermatosoidide arv ja testosteroonisisaldus.
English: On 25 January 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product EnCyzix, intended for the treatment of hypogonadotropic hypogonadism in men.
Estonian: 25. jaanuaril 2018 võttis inimravimite komitee vastu negatiivse arvamuse, soovitades keelduda ravimi EnCyzix müügiloa andmisest; ravimit kavatseti kasutada hüpogonadotroopse hüpogonadismi raviks meestel.
English: Refusal of the marketing authorisation for EnCyzix (enclomifene) EMA/CHMP/54473/2018
Estonian: EnCyzixi (enklomifeen) müügiloa andmisest keeldumine EMA/CHMP/54473/2018
English: EnCyzix was to be used in overweight men with a body mass index (BMI) of at least 25 kg/m2.
Estonian: EnCyzixi kavatseti kasutada ülekaalulistel meestel, kelle kehamassi indeks on vähemalt 25 kg/m2.
English: Therefore, the CHMP was of the opinion that the benefits of EnCyzix did not outweigh its risks and recommended that it be refused marketing authorisation.
Estonian: Inimravimite komitee oli seepärast arvamusel, et EnCyzixi kasulikkus ei ole suurem kui sellega kaasnevad riskid, ja soovitas müügiloa andmisest keelduda.
English: Refusal of the marketing authorisation for EnCyzix (enclomifene)
Estonian: EnCyzixi (enklomifeen) müügiloa andmisest keeldumine
English: EnCyzix is a medicine that contains the active substance enclomifene.
Estonian: EnCyzix on ravim, mis sisaldab toimeainena enklomifeeni.
English: In this condition, the sex organs (the testes in men) do not work properly resulting in symptoms such as infertility, low libido, impotence, weakened bones and weight gain.
Estonian: Selle seisundi korral ei toimi suguelundid (meestel munandid) normaalselt, mille tulemusena tekivad sellised sümptomid nagu viljatus, libiido langus, impotentsus, luude nõrgenemine ja kehakaalu tõus.
English: How does EnCyzix work?
Estonian: Kuidas EnCyzix toimib?
English: The CHMP noted that although the studies showed an increase in testosterone levels with EnCyzix, they did not look at whether EnCyzix would improve symptoms such as bone strength, weight gain, impotence and libido.
Estonian: Inimravimite komitee märkis, et kuigi uuringutes täheldati EnCyzixi kasutamisel testosteroonisisalduse suurenemist, ei uuritud seda, kas EnCyzix parandab ka sellised sümptomeid nagu luude tihedus, kehakaalu tõus, impotentsus ja libiido.
English: EnCyzix blocks the excess oestrogen enabling release of gonadotrophins and normal testicular function.
Estonian: EnCyzix blokeerib ülemäärase östrogeeni, võimaldades gonadotropiinide vabanemist ja normaliseerides munandite funktsiooni.
English: Patients were given either EnCyzix, or placebo (a dummy treatment) with and without application of a testosterone gel.
Estonian: Patsiendid kasutasid kas EnCyzixi või platseebot (näiv ravim) koos testosteroonigeeliga või ilma.
English: The company informed the CHMP that there are no ongoing clinical trials or compassionate use programmes with EnCyzix.
Estonian: Ettevõte teatas inimravimite komiteele, et EnCyzixi kliinilisi uuringuid või eriloaga kasutamise programme praegu ei toimu.
English: EnCyzix was expected to be used to treat hypogonadotropic hypogonadism in men.
Estonian: EnCyzixi kavatseti kasutada hüpogonadotroopse hüpogonadismi raviks meestel.
English: In addition, there is a risk of venous thromboembolism (problems due to the formation of blood clots in the veins) with the medicine.
Estonian: Peale selle esineb ravimi kasutamisega seoses venoosse trombemboolia (trombidest ehk soonesisestest verehüüvetest põhjustatud probleemid) risk.
English: What were the CHMP's main concerns that led to the refusal?
Estonian: Mis olid peamised põhjused, mille tõttu inimravimite komitee soovitas müügiloa andmisest keelduda?
English: What was EnCyzix expected to be used for?
Estonian: Milleks kavatseti EnCyzixi kasutada?
English: Following this, 51 of the patients went on to be followed up for an average of three and a half more years.
Estonian: Seejärel jälgiti 51 patsienti keskmiselt kolm ja pool aastat.
English: Thyrogen must not be used during pregnancy.
Estonian: Thyrogeni ei tohi kasutada raseduse ajal.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Thyrogen on 9 March 2000.
Estonian: Euroopa Komisjon andis Thyrogeni müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 9. Märtsil 2000.
English: The full EPAR for Thyrogen can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Thyrogeni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This included 25 patients using Thyrogen and 18 whose replacement therapy was stopped.
Estonian: Nende seas oli 25 patsienti, kes kasutasid Thyrogeni, ja 18 patsienti, kelle asendusravi peatati.
English: Other information about Thyrogen
Estonian: Muu teave Thyrogeni kohta
English: This finding was confirmed in the follow-up study: all 43 patients whose results could be evaluated after a further three and a half years had successful treatment.
Estonian: Seda kinnitas ka järeluuring: kõigil 43 patsiendil, kelle tulemusi kolme ja poole aasta pärast hinnati, oli ravi olnud edukas.
English: This is a summary of the European public assessment report (EPAR) for Thyrogen.
Estonian: See on ravimi Thyrogen Euroopa avaliku hindamisaruande kokkuvõte.
English: The CHMP decided that Thyrogen's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Thyrogeni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The company also presented the results of 13 studies from the published literature, including one key study that compared the effect of Thyrogen and the effect of stopping replacement therapy in 394 patients who were followed up for around two and a half years.
Estonian: Ettevõte esitas avaldatud teaduskirjandusest ka 13 uuringu, sealhulgas ühe põhiuuringu andmed, kus võrreldi Thyrogeni toimet ja asendusravi peatamise toimet 394 patsiendil, keda jälgiti kuni ligikaudu kaks ja pool aastat.
English: For more information about treatment with Thyrogen, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Thyrogeniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The most common side effect with Thyrogen (seen in more than 1 patient in 10) is nausea (feeling sick).
Estonian: Thyrogeni kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on iiveldus.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Thyrogen.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Thyrogen should not be used in people who may be hypersensitive (allergic) to bovine (cow) or human TSH or to any of the other ingredients.
Estonian: Thyrogeni ei tohi kasutada patsiendid, kes võivad olla veise või inimese TSH või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: For eliminating remaining thyroid tissue following thyroid cancer surgery, both treatments were 100% successful after eight months.
Estonian: Kilpnäärme kirurgilise eemaldamise järel säilinud kilpnäärmekoe hävitamisel olid kaheksa kuu pärast mõlemad raviviisid 100% edukad.
English: Thyrogen thyrotropin alfa
Estonian: Thyrogen alfatüreotropiin
English: The iodine is given 24 hours after the last Thyrogen injection and scan is performed 48 to 72 hours later.
Estonian: Joodi manustatakse 24 tundi pärast viimast Thyrogeni süsti ja piltdiagnostikauuring tehakse 48-72 tunni pärast.
English: The results of the two measurements were compared to see if they were in agreement.
Estonian: Võrreldi mõõtmistulemuste kooskõla.
English: This study also compared Thyrogen with the patients' own TSH.
Estonian: Uuringus võrreldi Thyrogeni patsiendi enda TSH-ga.
English: Thyrogen can also be used in combination with radioactive iodine to ablate (eliminate) any remaining thyroid tissue in patients who have had all or almost all of their thyroid gland removed and whose cancer has not spread to other parts of the body.
Estonian: Thyrogeni tohib kasutada ka koos radioaktiivse joodiga võimaliku säilinud kilpnäärmekoe ablatsiooniks (hävitamiseks) patsientidel, kelle kogu või peaaegu kogu kilpnääre on eemaldatud ja kelle vähk ei ole levinud organismis mujale.
English: The main measure of effectiveness was based on a test to see if the patient had any thyroid tissue remaining at eight months after treatment.
Estonian: Efektiivsuse põhinäitaja tugines analüüsile, milles uuriti kilpnäärmekoe esinemist kaheksa kuud pärast ravi.
English: For the full list of all side effects reported with Thyrogen, see the package leaflet.
Estonian: Thyrogeni kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Why has Thyrogen been approved?
Estonian: Miks Thyrogen heaks kiideti?
English: Thyrotropin alfa is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes the cell able to produce the hormone.
Estonian: Alfatüreotropiini valmistatakse rekombinant-DNA-tehnika abil: seda toodab rakk, millele on lisatud hormooni teket võimaldav geen (DNA).
English: Thyrogen used with lower doses of radioactive iodine was also shown to be effective.
Estonian: Tõendati ka, et Thyrogeni kasutamine koos radioaktiivse joodi väiksemate annustega on samuti efektiivne.
English: When Thyrogen is used to eliminate left-over thyroid tissue, radioactive iodine is also given 24 hours after the last Thyrogen injection.
Estonian: Kui Thyrogeni kasutatakse säilinud kilpnäärmekoe hävitamiseks, manustatakse radioaktiivset joodi samuti 24 tundi pärast viimast Thyrogeni süsti.
English: The published studies showed that using Thyrogen was also effective in low-risk patients when leftover tissue was detected only by measuring thyroglobulin levels and that it was not always necessary to do a radioactive iodine scan.
Estonian: Avaldatud uuringute andmetel on Thyrogen efektiivne ka väikese riskiga patsientidel, kelle säilinud kude sai tuvastada ainult türeoglobuliini sisalduse mõõtmisega, ja radioaktiivse joodiga uuringut ei olnud alati vaja.
English: Using Thyrogen to detect left over thyroid tissue following surgery was comparable with using the patients' own TSH after their replacement therapy was stopped.
Estonian: Thyrogeni toime säilinud kilpnäärmekoe tuvastamisel pärast kilpnäärme kirurgilist eemaldamist oli võrreldav patsiendi enda TSH toimega pärast asendusravi peatamist.
English: Thyrogen was used to eliminate any left-over thyroid tissue in a study involving 63 patients with thyroid cancer who were given higher doses of radioactive iodine.
Estonian: Thyrogeni kasutati säilinud kilpnäärmekoe hävitamiseks uuringus, milles osales 63 kilpnäärmevähiga patsienti, kes said radioaktiivse joodi suuremaid annuseid.
English: However, patients who have had their thyroid gland removed receive medication (thyroid hormone replacement therapy) that stops their production of TSH.
Estonian: Patsiendid, kellel on kilpnääre eemaldatud, saavad ravimit (kilpnäärmehormooni asendusravi), mis peatab TSH tekkimise organismis.
English: The company also presented the results of studies from the published literature looking at Thyrogen's effect when it was used with a thyroglobulin test, but without a radioactive iodine scan.
Estonian: Ettevõte esitas teaduskirjandusest ka selliste uuringute andmed, kus jälgiti Thyrogeni toimet, kui seda kasutati koos türeoglobuliini analüüsiga, kuid ilma radioaktiivse joodiga toimuva piltdiagnostikauuringuta.